Formulation study of duloxetine hydrochloride enteric-coated tablets
Abstract During storage, duloxetine hydrochloride may have an unexpected cross reaction with enteric coated acrylic resin, which may affect the product quality. Solve the problem of cross-reaction between the Duloxetine enteric-coated tablets core and coated enteric materials and improve the quality...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2023-01-01
|
| Series: | SN Applied Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s42452-023-05290-2 |
| _version_ | 1828051594045816832 |
|---|---|
| author | Jiang Guowei Cao Zhihui Zhang Yuhan Meng Yongjun Yi Qingqing |
| author_facet | Jiang Guowei Cao Zhihui Zhang Yuhan Meng Yongjun Yi Qingqing |
| author_sort | Jiang Guowei |
| collection | DOAJ |
| description | Abstract During storage, duloxetine hydrochloride may have an unexpected cross reaction with enteric coated acrylic resin, which may affect the product quality. Solve the problem of cross-reaction between the Duloxetine enteric-coated tablets core and coated enteric materials and improve the quality of the products. Duloxetine enteric-coated tablets’ core formulation and isolation layer prescription were designed and compared with duloxetine enteric-coated tablets sold on the market. Then, we measured the dissolution rate, content, and releasing rate of prepared duloxetine enteric-coated tablets. In the formulation of tablets core, prescription 3 had advantages in particle mobility, disintegration time, and dissolution rate. Prescription 5 was stable during the coating process, and the dissolution residue in the cup was relatively good, showing obvious dissolution advantages. Thus, prescription 5 was selected as the isolation layer prescription. The most suitable adhesive for the preparation of Duloxetine hydrochloride enteric-coated tablets was povione K30 dissolved in ethanol solution with 1/2 of the prescription amount. When 1.3 g colloidal silica was added to the prescription and the dosage of magnesium stearate was 1.48 g, the dissolution rate of the drug could be relatively improved. The ratio of sucrose and talc was 138/8.7, which could effectively configure the coating solution with a solid content of 15–20% to make the coating smooth. |
| first_indexed | 2024-04-10T19:41:04Z |
| format | Article |
| id | doaj.art-83aee1dd6d6e4e24aa03b6a459348155 |
| institution | Directory Open Access Journal |
| issn | 2523-3963 2523-3971 |
| language | English |
| last_indexed | 2024-04-10T19:41:04Z |
| publishDate | 2023-01-01 |
| publisher | Springer |
| record_format | Article |
| series | SN Applied Sciences |
| spelling | doaj.art-83aee1dd6d6e4e24aa03b6a4593481552023-01-29T12:19:06ZengSpringerSN Applied Sciences2523-39632523-39712023-01-01521810.1007/s42452-023-05290-2Formulation study of duloxetine hydrochloride enteric-coated tabletsJiang Guowei0Cao Zhihui1Zhang Yuhan2Meng Yongjun3Yi Qingqing4Pharmacy Department, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health SciencesPharmacy Department, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health SciencesSchool of Pharmacy, Shanghai University of Medicine and Health SciencesPharmacy Department, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health SciencesClinical Research Center, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health SciencesAbstract During storage, duloxetine hydrochloride may have an unexpected cross reaction with enteric coated acrylic resin, which may affect the product quality. Solve the problem of cross-reaction between the Duloxetine enteric-coated tablets core and coated enteric materials and improve the quality of the products. Duloxetine enteric-coated tablets’ core formulation and isolation layer prescription were designed and compared with duloxetine enteric-coated tablets sold on the market. Then, we measured the dissolution rate, content, and releasing rate of prepared duloxetine enteric-coated tablets. In the formulation of tablets core, prescription 3 had advantages in particle mobility, disintegration time, and dissolution rate. Prescription 5 was stable during the coating process, and the dissolution residue in the cup was relatively good, showing obvious dissolution advantages. Thus, prescription 5 was selected as the isolation layer prescription. The most suitable adhesive for the preparation of Duloxetine hydrochloride enteric-coated tablets was povione K30 dissolved in ethanol solution with 1/2 of the prescription amount. When 1.3 g colloidal silica was added to the prescription and the dosage of magnesium stearate was 1.48 g, the dissolution rate of the drug could be relatively improved. The ratio of sucrose and talc was 138/8.7, which could effectively configure the coating solution with a solid content of 15–20% to make the coating smooth.https://doi.org/10.1007/s42452-023-05290-2Duloxetine enteric-coated tabletsTablet coreCoating materialPrescription processDissolution rateDisintegration time |
| spellingShingle | Jiang Guowei Cao Zhihui Zhang Yuhan Meng Yongjun Yi Qingqing Formulation study of duloxetine hydrochloride enteric-coated tablets SN Applied Sciences Duloxetine enteric-coated tablets Tablet core Coating material Prescription process Dissolution rate Disintegration time |
| title | Formulation study of duloxetine hydrochloride enteric-coated tablets |
| title_full | Formulation study of duloxetine hydrochloride enteric-coated tablets |
| title_fullStr | Formulation study of duloxetine hydrochloride enteric-coated tablets |
| title_full_unstemmed | Formulation study of duloxetine hydrochloride enteric-coated tablets |
| title_short | Formulation study of duloxetine hydrochloride enteric-coated tablets |
| title_sort | formulation study of duloxetine hydrochloride enteric coated tablets |
| topic | Duloxetine enteric-coated tablets Tablet core Coating material Prescription process Dissolution rate Disintegration time |
| url | https://doi.org/10.1007/s42452-023-05290-2 |
| work_keys_str_mv | AT jiangguowei formulationstudyofduloxetinehydrochlorideentericcoatedtablets AT caozhihui formulationstudyofduloxetinehydrochlorideentericcoatedtablets AT zhangyuhan formulationstudyofduloxetinehydrochlorideentericcoatedtablets AT mengyongjun formulationstudyofduloxetinehydrochlorideentericcoatedtablets AT yiqingqing formulationstudyofduloxetinehydrochlorideentericcoatedtablets |